Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes
Abstract The rapidly aging population is fueling a surge in diabetes, especially Type 2, which heightens colorectal cancer (CRC) risk. Colorectal adenoma, a precursor, compounds this trend. Although alpha-glucosidase inhibitors are effective hypoglycemic drugs working in the GI tract, the link betwe...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84294-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559701013135360 |
|---|---|
| author | Dingchao Xia Lanling Jin Binfeng Wang Yi Jin Qun Zheng Jie Xu Senzhong Chen |
| author_facet | Dingchao Xia Lanling Jin Binfeng Wang Yi Jin Qun Zheng Jie Xu Senzhong Chen |
| author_sort | Dingchao Xia |
| collection | DOAJ |
| description | Abstract The rapidly aging population is fueling a surge in diabetes, especially Type 2, which heightens colorectal cancer (CRC) risk. Colorectal adenoma, a precursor, compounds this trend. Although alpha-glucosidase inhibitors are effective hypoglycemic drugs working in the GI tract, the link between them and colorectal adenoma formation remains unexplored. A retrospective cross-sectional study was conducted on type 2 diabetes patients aged 60 and above using data from Wenzhou Central Hospital from January 2021 to May 2024. We used multivariable logistic regression and propensity score matching analysis (PSM) to calculate adjusted ORs for colorectal adenoma, controlling for potential confounders. A total of 311 subjects were enrolled in the study, with a mean age of 67.55 years. 138 (44.4%) were diagnosed with colorectal adenoma. Multivariate logistic regression analysis revealed that the AGI (Alpha-glucosidase inhibitor) Group had an adjusted OR of 0.399 (95% CI = 0.22–0.723, p = 0.002) compared to those with AGI free people. A similar trend was also observed in the PSM analysis (OR = 0.362, 95% CI = 0.176–0.744, p = 0.004). Subgroup analysis reveals hypertension as a potential modulator of the inverse relationship between AGI and colorectal adenoma occurrence post-PSM (p = 0.049). And AGI reduces serum iron levels, both before (p = 0.01) and after PSM (p = 0.028). In summary, our findings indicate that AGI significantly mitigates the risk of colorectal adenoma among individuals aged 60 and above, particularly among those afflicted with hypertension. Additionally, it substantially decreases serum iron levels. |
| format | Article |
| id | doaj-art-e5843b7542c943338f1f29ab9a4a3a4f |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e5843b7542c943338f1f29ab9a4a3a4f2025-01-05T12:16:48ZengNature PortfolioScientific Reports2045-23222025-01-0115111110.1038/s41598-024-84294-3Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetesDingchao Xia0Lanling Jin1Binfeng Wang2Yi Jin3Qun Zheng4Jie Xu5Senzhong Chen6Department of Infectious Diseases, Wenzhou Central HospitalDepartment of Neurology, Pujiang County People’s HospitalDepartment of Gastroenterology, Affiliated Yueqing Hospital,Wenzhou Medical UniversityDepartment of Rheumatology, The Second Affiliated Hospital of Wenzhou Medical UniversityDepartment of Rheumatology, The Second Affiliated Hospital of Wenzhou Medical UniversityDepartment of Rheumatology, The Second Affiliated Hospital of Wenzhou Medical UniversityDepartment of Gerontology, Wenzhou Central HospitalAbstract The rapidly aging population is fueling a surge in diabetes, especially Type 2, which heightens colorectal cancer (CRC) risk. Colorectal adenoma, a precursor, compounds this trend. Although alpha-glucosidase inhibitors are effective hypoglycemic drugs working in the GI tract, the link between them and colorectal adenoma formation remains unexplored. A retrospective cross-sectional study was conducted on type 2 diabetes patients aged 60 and above using data from Wenzhou Central Hospital from January 2021 to May 2024. We used multivariable logistic regression and propensity score matching analysis (PSM) to calculate adjusted ORs for colorectal adenoma, controlling for potential confounders. A total of 311 subjects were enrolled in the study, with a mean age of 67.55 years. 138 (44.4%) were diagnosed with colorectal adenoma. Multivariate logistic regression analysis revealed that the AGI (Alpha-glucosidase inhibitor) Group had an adjusted OR of 0.399 (95% CI = 0.22–0.723, p = 0.002) compared to those with AGI free people. A similar trend was also observed in the PSM analysis (OR = 0.362, 95% CI = 0.176–0.744, p = 0.004). Subgroup analysis reveals hypertension as a potential modulator of the inverse relationship between AGI and colorectal adenoma occurrence post-PSM (p = 0.049). And AGI reduces serum iron levels, both before (p = 0.01) and after PSM (p = 0.028). In summary, our findings indicate that AGI significantly mitigates the risk of colorectal adenoma among individuals aged 60 and above, particularly among those afflicted with hypertension. Additionally, it substantially decreases serum iron levels.https://doi.org/10.1038/s41598-024-84294-3AgedColorectal adenomaT2DMAlpha-glucosidase inhibitor |
| spellingShingle | Dingchao Xia Lanling Jin Binfeng Wang Yi Jin Qun Zheng Jie Xu Senzhong Chen Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes Scientific Reports Aged Colorectal adenoma T2DM Alpha-glucosidase inhibitor |
| title | Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes |
| title_full | Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes |
| title_fullStr | Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes |
| title_full_unstemmed | Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes |
| title_short | Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes |
| title_sort | alpha glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with type 2 diabetes |
| topic | Aged Colorectal adenoma T2DM Alpha-glucosidase inhibitor |
| url | https://doi.org/10.1038/s41598-024-84294-3 |
| work_keys_str_mv | AT dingchaoxia alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT lanlingjin alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT binfengwang alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT yijin alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT qunzheng alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT jiexu alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes AT senzhongchen alphaglucosidaseinhibitordecreasestheriskofcolorectaladenomaintheagedwithtype2diabetes |